OTC:PURE
PURE BIOSCIENCE, INC.
A clinical-stage biotech firm advancing novel treatments for metabolic diseases like diabetes and obesity with a focus on proprietary platform technologies.
Key Metrics
Investment Thesis
Bull Case
The company demonstrates improving operational efficiency with revenue growing from $1.9M to $2.2M over the last three years while net losses narrowing sequentially, indicating potential cost management improvements as the pipeline matures. If key clinical candidates advance successfully, the current low market capitalization could offer substantial upside if the company secures strategic partnerships or achieves regulatory approval for its metabolic disease portfolio.
Bear Case
The severe liquidity crisis with only $334K in cash against $6.2M in liabilities and a massive retained earnings deficit of -$139M creates an existential threat that requires immediate external financing likely at high costs or dilution. The persistent negative operating cash flow of -$2.0M suggests the business model cannot yet generate self-sustaining growth, making it highly vulnerable to market downturns or failed clinical trials.
About PURE BIOSCIENCE, INC.
Pure Bioscience is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic disorders, primarily targeting type 2 diabetes and obesity. The company leverages its proprietary technologies to advance candidates through preclinical and clinical development stages while managing limited current revenue streams from strategic partnerships or licensing.
Analysis
Management Discussion
Despite a slight improvement in net loss from -$4.0M in 2023 to -$2.4M in the most recent period, the company continues to operate at a significant deficit with revenue growth outpacing profitability by a wide margin. The balance sheet shows deteriorating equity of -$5.1M and negative cash flow from operations of $2.0M, suggesting that current financial resources are insufficient to sustain operations without additional capital raising or successful milestone payments.
Industry Overview
The metabolic disease sector is experiencing a surge in innovation driven by aging demographics and rising prevalence of type 2 diabetes and obesity, attracting significant venture capital and strategic interest from major pharmaceutical players. Success in this space often requires substantial upfront R&D investment with long development timelines and high regulatory hurdles before products can generate meaningful commercial revenue.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $1.9M | $2.0M | $2.2M |
| Cost of Revenue | $906.0K | $811.0K | $899.0K |
| Gross Profit | $971.0K | $1.2M | $1.3M |
| Operating Expenses | $4.9M | $4.3M | $3.6M |
| Operating Income | $-3.9M | $-3.2M | $-2.3M |
| R&D | $297.0K | $302.0K | $316.0K |
| G&A | $4.3M | $4.0M | $3.3M |
| Stock-Based Comp | $324.0K | $214.0K | $147.0K |
| D&A | $117.0K | $148.0K | $2.0K |
| Depreciation | $117.0K | $148.0K | $2.0K |
| Other OpEx | $315.0K | $60.0K | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Expense | $14.0K | — | — |
| Pre-Tax Income | $-3.9M | $-3.2M | $-2.3M |
| Income Tax | $1.6K | $0 | $0 |
| Continuing Ops | $-3.9M | $-3.2M | $-2.3M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-4.0M | $-3.4M | $-2.4M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-4.0M | $-3.4M | $-2.4M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $1.6M | $805.0K | $1.0M |
| Cash & Equivalents | $1.1M | $349.0K | $334.0K |
| Accounts Receivable | $285.0K | $298.0K | $474.0K |
| Inventory | $88.0K | $56.0K | $141.0K |
| Other Current Assets | $136.0K | $102.0K | $98.0K |
| Long-Term Assets | $221.0K | $13.0K | $11.0K |
| PP&E (Net) | $221.0K | $13.0K | $11.0K |
| Other LT Assets | $0 | $0 | $0 |
| Total Assets | $1.8M | $818.0K | $1.1M |
| Current Liabilities | $532.0K | $733.0K | $938.0K |
| Accounts Payable | $422.0K | $601.0K | $784.0K |
| Other Current Liab | $0 | $0 | $0 |
| Long-Term Liabilities | $1.0M | $2.9M | $5.2M |
| Total Liabilities | $1.6M | $3.7M | $6.2M |
| Shareholders' Equity | $272.0K | $-2.9M | $-5.1M |
| Paid-In Capital | $132.4M | $132.6M | $132.8M |
| Retained Earnings | $-133.2M | $-136.6M | $-139.0M |
| Total L&E | $1.8M | $818.0K | $1.1M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $-4.0M | $-3.4M | $-2.4M |
| Non-Cash Adjustments | $650.0K | $528.0K | $-365.0K |
| Working Capital Changes | $33.0K | $291.0K | $749.0K |
| Cash from Operations | $-3.3M | $-2.5M | $-2.0M |
| Capital Expenditures | $33.0K | — | — |
| Cash from Investing | $-33.0K | $0 | $0 |
| Cash from Financing | $1.0M | $1.8M | $2.0M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-2.3M | $-746.0K | $-15.0K |
| Beginning Cash | $3.5M | $1.2M | $424.0K |
| Ending Cash | $1.2M | $424.0K | $409.0K |
Frequently Asked Questions
How does PURE BIOSCIENCE, INC. make money?
The company's financial profile reflects operations primarily centered on research and development of proprietary drug candidates, likely supported by potential revenue from collaboration agreements or licensing deals given the low current asset base relative to liabilities. Operations are concentrated in clinical-stage assets rather than commercial sales, with expenses heavily weighted toward general and administrative functions and R&D activities totaling over $3 million.
What are the main risks for PURE?
Significant cash burn with a net loss of $2.4M in the latest period despite minimal revenue generation, substantial accumulated deficit exceeding $139M indicating high capital needs, limited liquidity with only $334K in cash on hand against $6.2M in total liabilities, and reliance on successful clinical trial outcomes to secure future financing.
What is PURE's competitive advantage?
Access to proprietary technologies for targeting metabolic pathways, potentially differentiated chemistry platforms that reduce development risk, and strategic partnerships that may provide non-dilutive funding or commercial support for pipeline assets.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.